Exagen Inc. (NASDAQ:XGN – Get Free Report) major shareholder Jorey Chernett sold 109,436 shares of the stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $4.65, for a total value of $508,877.40. Following the completion of the transaction, the insider directly owned 2,587,504 shares in the company, valued at $12,031,893.60. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Friday, November 13th, Jorey Chernett sold 58,068 shares of Exagen stock. The stock was sold at an average price of $4.08, for a total value of $236,917.44.
- On Wednesday, November 11th, Jorey Chernett acquired 71,315 shares of Exagen stock. The stock was purchased at an average price of $5.23 per share, with a total value of $372,977.45.
- On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The stock was sold at an average price of $6.14, for a total value of $69,167.10.
- On Tuesday, November 10th, Jorey Chernett bought 7,085 shares of Exagen stock. The stock was purchased at an average price of $5.26 per share, for a total transaction of $37,267.10.
- On Monday, November 9th, Jorey Chernett bought 8,500 shares of Exagen stock. The stock was purchased at an average price of $6.35 per share, for a total transaction of $53,975.00.
- On Monday, October 19th, Jorey Chernett purchased 14,000 shares of Exagen stock. The stock was acquired at an average price of $7.46 per share, for a total transaction of $104,440.00.
Exagen Stock Performance
NASDAQ:XGN traded down $0.28 during midday trading on Friday, hitting $4.13. The company’s stock had a trading volume of 3,356,140 shares, compared to its average volume of 581,895. Exagen Inc. has a fifty-two week low of $2.59 and a fifty-two week high of $9.28. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.46 and a quick ratio of 3.18. The firm has a market cap of $105.36 million, a P/E ratio of -5.51 and a beta of 2.25. The firm’s 50 day moving average is $7.71 and its 200-day moving average is $5.13.
Exagen (NASDAQ:XGN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The business had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.34 million. Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%. Equities analysts anticipate that Exagen Inc. will post -0.71 earnings per share for the current fiscal year.
Institutional Trading of Exagen
A number of hedge funds have recently added to or reduced their stakes in XGN. Jump Financial LLC raised its position in shares of Exagen by 596.9% in the third quarter. Jump Financial LLC now owns 81,714 shares of the company’s stock worth $664,000 after acquiring an additional 69,989 shares during the period. Flputnam Investment Management Co. boosted its stake in shares of Exagen by 3.8% during the 3rd quarter. Flputnam Investment Management Co. now owns 299,828 shares of the company’s stock worth $2,438,000 after acquiring an additional 11,018 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Exagen by 28.1% during the 3rd quarter. Marshall Wace LLP now owns 392,789 shares of the company’s stock worth $3,193,000 after acquiring an additional 86,086 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Exagen during the 3rd quarter valued at about $198,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Exagen during the 3rd quarter valued at about $418,000. 75.25% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on XGN shares. BTIG Research reaffirmed a “buy” rating and set a $9.00 price target on shares of Exagen in a research report on Wednesday. TD Cowen boosted their price objective on Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Wall Street Zen downgraded Exagen from a “hold” rating to a “sell” rating in a research note on Saturday. B. Riley Financial started coverage on Exagen in a report on Friday, September 11th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Canaccord Genuity Group reduced their price target on Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.88.
Read Our Latest Stock Analysis on Exagen
About Exagen
Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.
Featured Stories
- Five stocks we like better than Exagen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
